OPP003_ChronicPainDTx 📄 Overview A prescription Digital Therapeutic (DTx) SaMD for chronic non-malignant pain, leveraging cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and mindfulness principles. It integrates biofeedback from wearable sensors (e.g., HRV, galvanic skin response) with an AI-driven personalized curriculum, interactive modules, and gamified challenges to teach pain coping skills, track progress, and reduce reliance on pharmacotherapy. Key technologies: 👤 Target users: 👍 Benefits Reduced pain severity and interference with daily life • Improved functional capacity and quality of life • Decreased opioid reliance and associated risks • Enhanced patient self-management and coping skills • Scalable, evidence-based alternative/adjunct to traditional therapies Use bullets or new lines. 👎 Challenges Ensuring long-term patient adherence and sustained engagement • Demonstrating superior efficacy compared to standard care or other DTx • Establishing clear reimbursement pathways and formulary inclusion • Addressing the heterogeneity of chronic pain conditions and patient responses • Integration into existing pain management care pathways 📋 Regulatory & Validation Likely Class II or III SaMD, depending on risk profile and claims (e.g., opioid reduction). • Requires robust clinical trial evidence (RCTs) for efficacy and safety. • Adherence to GxP principles for software development and quality management.